Researchers have significantly improved its development of the new therapy for ATTR-CM, employing the compound. Initial patient data reveals promising improvements for patients diagnosed with a severe disease. This effort represents BridgeBio's focus to managing unmet patient needs in this heart disease field. Attruby: BridgeBio's Novel Approach t